NYSE:CANF

Can-Fite BioPharma (CANF) Stock Forecast, Price & News

$2.59

+0.10 (+4.02%)

(As of 09/26/2023 ET)

Compare

Today's Range: $2.48
▼
$2.62
50-Day Range: $2.49
▼
$3.12
52-Week Range: $1.52
▼
$9.00

Volume: 3,038 shs
Average Volume: 48,287 shs
Market Capitalization: $9.17 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: $23.00

About Can-Fite BioPharma (NYSE:CANF) Stock

Can-Fite BioPharma Ltd., a clinical-stage biopharmaceutical company, develops small molecule therapeutic products for the treatment of cancer, liver inflammatory diseases, and erectile dysfunction. The company's lead drug candidate Piclidenoson, which has been completed Phase III clinical trial for the treatment of psoriasis; and Phase II clinical trial for the treatment of COVID-19. It also develops Namodenoson that is in Phase III clinical trial for the treatment of hepatocellular carcinoma, as well as in Phase IIb trial for the treatment of non-alcoholic steatohepatitis; and CF602, which is in pre-clinical trial for the treatment of erectile dysfunction. In addition, the company develops commercial predictive biomarker blood test kit for A3AR. Can-Fite BioPharma Ltd. has license and collaboration agreement with CMS Medical to develop, manufacture, and commercialize Piclidenoson and Namodenoson; and collaboration agreement with Univo Pharmaceuticals to identify and co-develop specific formulations of cannabis components for the treatment of cancer, inflammatory, autoimmune, and metabolic diseases. The company was formerly known as Can-Fite Technologies Ltd. and changed its name to Can-Fite BioPharma Ltd. in January 2001. Can-Fite BioPharma Ltd. was incorporated in 1994 and is headquartered in Petah Tikva, Israel.

CANF Price History

30 days | 90 days | 365 days | Advanced Chart

CANF Stock News Headlines

September 19, 2023 | americanbankingnews.com

Can-Fite BioPharma (NYSE:CANF) Earns Hold Rating from Analysts at StockNews.com

September 7, 2023 | finance.yahoo.com

Can-Fite to Share with Investors Latest Oncology and Rare Genetic Disease Developments at the H.C. Wainwright 25th Annual Conference

September 27, 2023 | Legacy Research (Ad)

WARNING: Mandatory U.S. Dollar Recall is Weeks Away

If you have any U.S. dollars in your bank account… You must see this shocking video exposing the government’s new plan to recall the U.S. dollar. According to Business Insider, this recall “could be imminent.” And if you don’t prepare now, you could end up holding a bunch of worthless U.S. dollars.

September 1, 2023 | seekingalpha.com

Can-Fite Biopharma discloses $100M mixed shelf offering - filing

August 31, 2023 | finance.yahoo.com

Can-Fite Reports Second Quarter 2023 Financial Results & Progress in Two Pivotal Phase III Clinical Studies

August 24, 2023 | businesswire.com

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating ...

August 24, 2023 | finance.yahoo.com

Can-Fite Enters Rare Genetic Disease Field Based on impactful findings of a Fondazione Telethon and Naples University Researcher showing Piclidenoson is efficacious in Treating Lowe Syndrome

August 18, 2023 | markets.businessinsider.com

Can-Fite Submits Pediatric Study Plan To Allow Registration Of Piclidenoson

September 27, 2023 | Stansberry Research (Ad)

A 73-Year-Old Market Signal With 95% Accuracy Just Flashed

This signal has flashed just 24 times in the past 73 years – and it has signaled the exact moment to move your money with 95% accuracy. Now, it's flashing again. Discover where here.

August 18, 2023 | finance.yahoo.com

Can-Fite Submitted to FDA a Pediatric Plan to Allow Registration of Piclidenoson for the Treatment of Adolescents with Psoriasis

July 17, 2023 | finance.yahoo.com

Can-Fite: Granted Breakthrough Abstract Award for Namodenoson in Treatment of Advanced Liver Cancer by ASCO Conquer Cancer Foundation

July 11, 2023 | finance.yahoo.com

Presenting on the Emerging Growth Conference on July 12 & 13 Register Now

July 7, 2023 | finance.yahoo.com

Can-Fite to Present at the Emerging Growth Conference on July 13, 2023

June 29, 2023 | finance.yahoo.com

Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan

June 27, 2023 | thestreet.com

Can-Fite BioPharma (CANF) Stock Jumps on Positive Pre-Clinical Data

June 13, 2023 | msn.com

CANF Rises on IND Submission Plans in Pancreatic Cancer

June 13, 2023 | markets.businessinsider.com

Can-Fite To Seek FDA Clearance For Phase II Trial Of Namodenoson In Pancreatic Cancer

June 13, 2023 | finance.yahoo.com

Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson

June 2, 2023 | finance.yahoo.com

Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston

June 1, 2023 | finance.yahoo.com

Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update

May 30, 2023 | finance.yahoo.com

Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)

May 15, 2023 | benzinga.com

Can-Fite: Presenting Namodenoson's New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

May 15, 2023 | finance.yahoo.com

Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023

May 11, 2023 | markets.businessinsider.com

Pre-market Movers: GFAI, SONO, KLXE, CDNA, DMRC…

May 10, 2023 | finance.yahoo.com

All You Need to Know About Can-Fite Biopharma Ltd (CANF) Rating Upgrade to Buy

May 2, 2023 | finance.yahoo.com

Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists

April 26, 2023 | finanznachrichten.de

CAN-FITE BIOPHARMA LTD ADR

See More Headlines

Receive CANF Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Can-Fite BioPharma and its competitors with MarketBeat's FREE daily newsletter.

CANF Company Calendar

Last Earnings: 8/31/2023
Today: 9/27/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NYSE
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NYSE:CANF
CUSIP: N/A
CIK: 1536196
Web: www.canfite.com
Phone: 972-3-924-1114
Fax: 972-3924-9378
Employees: 8
Year Founded: N/A

Price Target and Rating

Average Stock Price Forecast: $23.00
High Stock Price Forecast: $34.00
Low Stock Price Forecast: $12.00
Forecasted Upside/Downside: +788.0%
Consensus Rating: Moderate Buy
Rating Score (0-4): 2.50
Research Coverage: 2 Analysts

Profitability

EPS (Most Recent Fiscal Year): ($3.06)
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-10,170,000.00
Net Margins: -1,231.78%
Pretax Margin: -1,255.93%
Return on Equity: -143.29%
Return on Assets: -84.01%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 4.89
Quick Ratio: 4.63

Sales & Book Value

Annual Sales: $810,000.00
Price / Sales: 11.32
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.33 per share
Price / Book: 1.95

Miscellaneous

Outstanding Shares: 3,540,000
Free Float: 3,512,000
Market Cap: $9.17 million
Optionable: Not Optionable
Beta: 1.30

13 Stocks Institutional Investors Won't Stop Buying

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

Dr. Pnina Fishman Ph.D. (Age 75)
Founder, Chief Scientific Officer & Exec. Chairman
Comp: $644k

Mr. Motti Farbstein (Age 59)
CEO & Chief Operating and Financial Officer
Comp: $414k

Dr. Sari Fishman Ph.D. (Age 51)
VP of Bus. Devel.
Comp: $325k

Dr. Ilan Cohn Ph.D. (Age 69)
Co-Founder & Director

Dr. Stephen A. Harrison FACP
M.D., Member of Clinical Advisory Board & Consulting Chief Medical Officer

Key Competitors

View All Competitors

CANF Stock - Frequently Asked Questions

Should I buy or sell Can-Fite BioPharma stock right now?: 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Can-Fite BioPharma in the last twelve months. There are currently 1 hold rating and 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" CANF shares.
View CANF analyst ratings or view top-rated stocks.
What is Can-Fite BioPharma's stock price forecast for 2023?: 2 Wall Street research analysts have issued 12 month price objectives for Can-Fite BioPharma's stock. Their CANF share price forecasts range from $12.00 to $34.00. On average, they predict the company's share price to reach $23.00 in the next year. This suggests a possible upside of 788.0% from the stock's current price.
View analysts price targets for CANF or view top-rated stocks among Wall Street analysts.
How have CANF shares performed in 2023?: Can-Fite BioPharma's stock was trading at $0.6130 on January 1st, 2023. Since then, CANF shares have increased by 322.5% and is now trading at $2.59.
View the best growth stocks for 2023 here.
How were Can-Fite BioPharma's earnings last quarter?: Can-Fite BioPharma Ltd. (NYSE:CANF) posted its quarterly earnings results on Thursday, August, 31st. The company reported ($0.40) EPS for the quarter, beating analysts' consensus estimates of ($0.54) by $0.14. The company had revenue of $0.20 million for the quarter, compared to analysts' expectations of $0.20 million. Can-Fite BioPharma had a negative net margin of 1,231.78% and a negative trailing twelve-month return on equity of 143.29%.

When did Can-Fite BioPharma's stock split?: Can-Fite BioPharma shares reverse split before market open on Monday, January 9th 2023. The 1-10 reverse split was announced on Monday, January 9th 2023. The number of shares owned by shareholders was adjusted after the market closes on Monday, January 9th 2023. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split.
What is Can-Fite BioPharma's stock symbol?: Can-Fite BioPharma trades on the New York Stock Exchange (NYSE) under the ticker symbol "CANF."
How do I buy shares of Can-Fite BioPharma?: Shares of CANF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is Can-Fite BioPharma's stock price today?: One share of CANF stock can currently be purchased for approximately $2.59.
How much money does Can-Fite BioPharma make?: Can-Fite BioPharma (NYSE:CANF) has a market capitalization of $9.17 million and generates $810,000.00 in revenue each year. The company earns $-10,170,000.00 in net income (profit) each year or ($3.06) on an earnings per share basis.
How can I contact Can-Fite BioPharma?: Can-Fite BioPharma's mailing address is 10 Bareket Street, Kiryat Matalon PO Box 7537, Petah Tikva 4951778, Israel. The official website for the company is www.canfite.com. The company can be reached via phone at 972-3-924-1114, via email at info@canfite.co.il, or via fax at 972-3924-9378.

This page (NYSE:CANF) was last updated on 9/27/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial